glp-1 inventor How Lotte Bjerre Knudsen helped kick off the Age of Wegovy In an interview with El

Bimagrumab addresses a critical unmet need. Mark Pruzanski The advantage: While people on GLP-1 agonists tend to gain back any weight lost if they stop taking the meds, that might not be the case for bimagrumab 12 weeks after their last dose, the people in the 1,000-person phase 2 trial had yet to regain any weight

The TRIUMPH-1 trial, which focuses on core obesity management, is expected to read out in mid-2026

While L-arginine was popular for its quick effects, it suffered from poor bioavailability due to rapid conversion by the arginase enzyme

A larger randomized placebo-controlled study investigating the effects of sulforaphane on schizophrenia is ongoing and is expected to end in July of 2019

Aim for at least 150 minutes weekly to boost metabolism and mood